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We investigated whether chronic rosuvastatin administration could improve the abnormalities of the circulating levels of vascular
dysfunction markers in pulmonary arterial hypertension (PAH). Sixty patients, aged 13 to 60 years, with idiopathic (N = 14) or
congenital heart disease-associated PAH (N = 46) were equally but randomly assigned to rosuvastatin treatment (10 mg a day,
orally) or placebo for 6 months in a blind fashion. Plasma levels of P-selectin, tissue-plasminogen activator and its inhibitor as
well as von Willebrand factor antigen were measured by enzyme-linked immunoassay before and after 1, 3, and 6 months of
treatment. Baseline levels of biomarkers were elevated (68, 16, 45 and 46% increase relative to controls, for P-selectin, von
Willebrand factor antigen, tissue-plasminogen activator and its inhibitor, respectively; P < 0.001). P-selectin values at baseline,
1, 3, and 6 months were 39.9 ± 18.5, 37.6 ± 14.6, 34.8 ± 14.6, and 35.4 ± 13.9 ng/mL, respectively, for the rosuvastatin group
and 45.7 ± 26.8, 48.0 ± 26.9, 48.1 ± 25.7, and 45.7 ± 25.6 ng/mL for the placebo group. The P-selectin level was lower in the
rosuvastatin group compared with placebo throughout treatment (P = 0.037, general linear model). A trend was observed
towards a decrease in tissue-plasminogen activator in the statin group (16% reduction, P = 0.094), with no significant changes
in the other markers. Since P-selectin is crucial in inflammation and thrombosis, its reduction by rosuvastatin is potentially
relevant in the pathophysiological scenario of PAH.
Key words: Pulmonary hypertension; Statins; Endothelial dysfunction; P-selectin; Tissue-plasminogen activator and inhibitor;
von Willebrand factor
Research supported by FAPESP (#05/50320-5).
Received January 22, 2008. Accepted August 14, 2008
Introduction
The treatment of pulmonary arterial hypertension (PAH)
has changed in the last decades with the development of
new drugs, including prostanoids, endothelin antagonists
and phosphodiesterase inhibitors (1-7). Most clinical stud-
ies have demonstrated beneficial effects of these drugs on
physical capacity, quality of life, hemodynamics, and sur-
vival. In the clinical setting, these agents were initially
proposed as vasodilators, but experimental data suggest
that they may also act on vessel walls. However, the
effects of drugs on circulating levels of vascular dysfunc-
tion markers and other biomarkers have been explored to
a lesser extent, mostly for prostacyclin administration (8-
11).
Vascular dysfunction (involving endothelial cells, plate-
lets and leukocytes) is an important event in PAH (12).
Altered circulating levels of endothelial markers have been
observed in association with increased risk of thrombosis
and decreased survival (13-15). Therefore, the improve-
ment of vascular dysfunction with drug therapy might have
an impact on the risk of thrombotic complications and
mortality in these patients. Statins are among the drugs
that have been proposed in this context. They are capable
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of reversing experimental pulmonary hypertension, an ef-
fect that may be related to over-expression or protection of
endothelial nitric oxide synthase (16,17) and/or changes in
the expression of several other genes associated with
inflammatory, proliferative and apoptotic mechanisms (18),
including the bone morphogenetic protein type II receptor
gene in human lung microvascular endothelial cells (19).
The present study was planned to investigate the ef-
fects of chronic statin administration versus placebo on the
circulating levels of vascular dysfunction markers in pa-
tients with either idiopathic PAH or that associated with
congenital heart disease. We also measured the 6-min
walked distance and resting as well as postexercise pe-
ripheral oxygen saturation as exploratory clinical variables.
Since a direct vasodilator effect of the drug was not ex-
pected, all patients with class III symptoms were assigned
to vasodilator therapy before they entered the study.
Material and Methods
Study population
Adolescents and adults with PAH, either idiopathic or
associated with congenital heart disease, in the absence
or presence of hypoxemia (resting SpO2 of ≥90 or <90%,
respectively) were enrolled. They were receiving medical
care at the Heart Institute, São Paulo, Brazil, as outpatients
with stable clinical conditions (functional class II or III, New
York Heart Association). A mean pulmonary arterial pres-
sure of >30 mmHg at rest was necessary for inclusion.
Patients with an angio CT showing extensive thrombotic
lesions in the pulmonary arteries were excluded. All pa-
tients with class III symptoms were started on vasodilator
therapy (oral sildenafil, 20-40 mg, three times a day) 1-2
months before entering the study. For patients with stable
class II symptoms, vasodilator therapy was considered
after completion of the present study. The majority of
patients were on chronic anticoagulant therapy with war-
farin, and some were using diuretics and/or digoxin. We
planned not to change baseline treatment during the study
period, unless clearly necessary in case of clinical deterio-
ration. All subjects with congenital heart disease had in-
creased pulmonary vascular resistance and were consid-
ered to be unsuitable for surgical correction. Those with
abnormal peripheral oxygen saturation were continuously
monitored in terms of hydration, hematocrit level, iron
stores, hyperviscosity symptoms, thrombotic or bleeding
episodes and need for hemodilution. The study protocol
was approved by the Scientific Committee of the Heart
Institute, and the Ethics Committee of the Hospital of
Clinics, School of Medicine, University of São Paulo. Writ-
ten informed consent was obtained from all patients (or
their parents in case of adolescents) before inclusion in the
study.
Randomization and study design
Despite the controversy about having variables under
control prior to randomization, for this specific study we
opted to ensure absolute group homogeneity regarding
four clinical variables. Thus, having met the inclusion
criteria, patients were consecutively organized into pairs
according to age (difference <10 years), diagnosis (idio-
pathic or congenital heart disease-associated PAH), rest-
ing peripheral oxygen saturation (<80, 80-89, ≥90%) and
use of vasodilator drugs. In each pair, 1 patient was ran-
domly assigned to placebo and the other to rosuvastatin
treatment, 10 mg/day, single oral dose (nested case-con-
trol randomized study). Randomization was carried out
using a pre-established computer-based sequence. The
operator was completely separated from patient care. Pa-
tients were maintained on treatment in a double-blind
fashion for 6 months, and the treatment code was opened
when the last patient completed the follow-up period.
Clinical and laboratory measurements
Demographic data were collected before treatment
was begun. The functional class, 6-min walked distance
and resting as well as postexercise (6-min walk) peripheral
oxygen saturation were recorded before and during treat-
ment (1, 3, and 6 months). For safety purposes, the circu-
lating levels of creatinine phosphokinase and hepatic en-
zymes (alanine, aspartate aminotransferases and γ-gluta-
myltranspeptidase) were determined at the same times.
Plasma levels of vascular dysfunction markers were
measured before treatment and 1, 3, and 6 months after
treatment using commercially available high-sensitivity
enzyme-linked immunosorbent assay kits purchased from
Diagnostica Stago, France, for tissue-plasminogen activa-
tor (t-PA), plasminogen activator inhibitor-1 (PAI-1), and
von Willebrand factor antigen (vWF:Ag) or from R&D Sys-
tems Inc., USA, for P-selectin. Determinations were car-
ried out in duplicate. Intra-assay variation and differences
between duplicates were always less than 5%. A control
plasma from our laboratory was run in parallel in all assays.
Corrections between assays (between kits) were never
necessary. Final results were obtained after normalization
for the hematocrit level.
A control group was selected, with the same age range
as the patients. The group consisted of 30 healthy volun-
teers, mostly blood donors. For inclusion, a brief question-
naire was applied in order to exclude acute or chronic
illness, in particular diabetes, hypertension and other car-
diovascular disorders. Only non-smokers were enrolled. A
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negative history for thrombophilia and/or deep vein throm-
bosis was an inclusion requirement.
Statistical analysis
Variables were tested for closeness to the normal
distribution, and results are reported as means and stand-
ard deviation (or standard error of the mean if specifically
indicated) or if not a normal distribution as median and
range. Baseline data were analyzed using the Student t-
test. The overall treatment effects on the biomarkers were
analyzed using a general linear model with two factors
(type of treatment and time), and repeated measures for
one of them (time). Thus, the study was primarily designed
to analyze the effect of the drug compared with placebo
during the entire 6-month period, not just at 6 months. PAI-
1 values were analyzed after logarithmic transformation. In
all tests, 0.05 was considered to be the level of signifi-
cance. Statistical analysis was carried out using the SPSS
statistical software, version 14.0 (SPSS Inc., USA).
Results
Sixty patients (36 females) were enrolled (N = 30 each
for placebo and statin groups), with age ranging from 13 to
60 years (median 33 years) and mean pulmonary arterial
pressure of 53 ± 16 mmHg. These patients were in func-
tional class II (N = 50) or III (N = 10), and the disease was
either idiopathic (N = 14) or associated with congenital
heart defects in the absence (N = 18) or presence (N = 28)
of hypoxemia. All subjects in functional class III had idio-
pathic pulmonary arterial hypertension and were on va-
sodilator therapy.
When all of the 60 class II or III patients on placebo or
drug were analyzed before treatment, the circulating levels
of the four biomarkers were higher (P < 0.001) when
compared with healthy controls (Table 1). Before treat-
ment, placebo and statin groups were similar in terms of
age, 6-min walked distance, peripheral oxygen saturation,
and plasma levels of all four biomarkers (Table 2).
The effects of rosuvastatin treatment on the biomar-
kers are shown in Figures 1 and 2. The P-selectin level was
significantly lower in the statin (filled circles) compared
with placebo (open circles) at all times during treatment (P
= 0.037). The placebo group P-selectin levels at 1, 3, and
6 months were 48.0 ± 26.9, 48.1 ± 25.7, and 45.7 ± 25.6 ng/
mL, respectively, and for the statin group, they were 37.6 ±
14.6, 34.8 ± 14.6, and 35.4 ± 13.9 ng/mL compared to
healthy controls, 25.5 ± 10.3 ng/mL and normal value
reported by the kit manufacturer, 29.0 ± 11.0 ng/mL. No
significant effects of rosuvastatin were observed for PAI-1
or von Willebrand factor, except for a trend towards a
Table 1. Plasma levels of biomarkers in patients (N = 60) and
controls (N = 30) before treatment.
Controls Patients
P-selectin (ng/mL) 25.5 ± 10.3 42.8 ± 23.0*
t-PA (ng/mL) 5.91 ± 1.71 8.57 ± 3.95*
vWF:Ag (U/dL) 105 ± 25 122 ± 23*
PAI-1 (ng/mL) 16.5 (5.2-42.9) 24.1 (9.7-134.7)*
Data are reported as mean ± SD, except for PAI-1 (median and
range). t-PA = tissue-type plasminogen activator; vWF:Ag = von
Willebrand factor antigen; PAI-1 = plasminogen activator inhibi-
tor-1.
*P < 0.001 (Student t-test).
Table 2. Placebo and rosuvastatin groups (N = 30 each) before
treatment.
Placebo Rosuvastatin
Age (years) 33.7 ± 11.1 34.6 ± 12.3
6MWD (m) 415 ± 110 416 ± 103
Rest SpO2 (%) 91 ± 4% 90 ± 6%
6MW SpO2 (%) 78 ± 12% 74 ± 17%
P-selectin (ng/mL) 45.7 ± 26.8 39.9 ± 18.5
t-PA (ng/mL) 9.00 ± 4.04 8.14 ± 3.38
vWF:Ag (U/dL) 122 ± 24 122 ± 22
PAI-1 (ng/mL) 23.9 (9.7-134.7) 24.5 (9.8-103.3)
Data are reported as mean ± SD, except for PAI-1 (median and
range). 6MWD = 6-min walked distance; SpO2 = peripheral
oxygen saturation; 6MW SpO2 = postexertional (6-min walk)
peripheral oxygen saturation; t-PA = tissue-type plasminogen
activator; vWF:Ag = von Willebrand factor antigen; PAI-1 = plas-
minogen activator inhibitor-1. There were no statistically signifi-
cant differences between groups for any of the parameters (Stu-
dent t-test).
decrease in t-PA levels (P = 0.094; Figure 1). There were
no statistical differences between patient subgroups (idio-
pathic versus congenital heart disease-associated PAH
and hypoxemic versus non-hypoxemic subjects).
In both placebo and rosuvastatin groups, no increase
in the 6-min walked distance was observed from baseline
to 6 months. In the specific diagnostic subgroup of hypox-
emic patients with congenital heart disease (N = 28), 8 of
14 patients on placebo, but only 1 of 14 patients on
rosuvastatin had a decrease in postexertional peripheral
oxygen saturation at 6 months compared with pretreat-
ment data (P = 0.013, Fisher exact test; Figure 3).
All patients completed the study, and the following
events were observed: clinical deterioration requiring com-
bined vasodilator therapy (1 patient, placebo group); he-
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Figure 1. Treatment-related behavior of endothelial markers in patients with pulmonary arterial hypertension. Before treatment with
rosuvastatin (10 mg/day), plasma levels of all four biomarkers were significantly higher (P values in the upper left side of the panels,
Student t-test) in patients (closed square) compared with controls (open square). Rosuvastatin (N = 30, closed circles) induced a
significant decrease in the circulating level of P-selectin compared with placebo (N = 30, open circles), with no significant effect on the
other markers. P values in the right side of the panels correspond to the analysis of the entire period of treatment (general linear model
for two factors). Results are reported as mean ± SEM for P-selectin, tissue-plasminogen activator (t-PA), and von Willebrand factor
antigen (vWF:Ag), and as median value and range for plasminogen activator inhibitor-1 (PAI-1).
moptysis (1 patient, statin group); syncope at 6 months
during the walk test (1 patient, placebo group); insomnia (3
patients, statin group); skeletal muscle pain (2 patients, 1
from statin group, with transient creatinine phosphokinase
elevation above three times normal level); γ-glutamyl-
transpeptidase elevation above three times normal (1 pa-
tient, placebo group).
Discussion
In this placebo-controlled study, chronic oral adminis-
tration of rosuvastatin to PAH patients resulted in a statis-
tically significant decrease in the circulating level of P-
selectin for an average of 10% and a trend towards a
decrease in t-PA level in patients with PAH (P = 0.094,
general linear model). The plasma levels of the other
markers of vascular dysfunction, vWF:Ag, tissue-plasmin-
ogen activator, and its inhibitor did not change with statin
treatment but were significantly higher than in healthy
subjects.
Only 1 patient presented transient elevation of plasma
creatinine phosphokinase level associated with skeletal
muscle pain attributable to rosuvastatin treatment. While
analyzing the options in terms of selecting the statin that
could be used in the present study, rosuvastatin was
chosen because it is a third-generation hydrophilic statin,
relatively well tolerated at daily doses of 10 to 40 mg, and
metabolized via cytochrome p450 (CYP) 2C9 and does not
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Figure 2. Plasma P-selectin levels in
patients with pulmonary arterial hy-
pertension. The results observed at
baseline and 6 months of treatment
with placebo (A, N = 30, open circles)
or rosuvastatin (B, N = 30, closed
circles) are shown (P = 0.0041 and P
= 0.9744 for rosuvastatin and placebo
groups, respectively, Student t-test).
Figure 3. Postexertional (6-min walk)
peripheral oxygen saturation (6MW
SpO2) in individual patients with pul-
monary hypertension associated with
congenital heart disease and hypox-
emia at rest. The results obtained at
baseline and 6 months of treatment
with placebo (A, N = 14, open circles)
or rosuvastatin (B, N = 14, closed
circles) are shown. Deterioration oc-
curred to a lesser extent in the rosu-
vastatin group compared with pa-
tients on placebo. The mean ± SD
values of 6MW SpO2 at baseline and
6 months, respectively, were 70 ± 9
and 68 ± 13% for the placebo group
(P = 0.6106, Student t-test), and 61 ±
14 and 64 ± 16% for the statin group
(P = 0.0129, Student t-test).
interact with many drugs that use the CYP 3A4 pathway
(20-22).
Beneficial effects of statins have been reported in
experimental pulmonary hypertension, particularly in hy-
poxic conditions (23-25). These effects may be related, in
part, to protection of endothelial cell nitric oxide synthase
(26), but changes in the expression of several genes
associated with inflammation, cell proliferation and apop-
tosis have been reported (18,19).
Two of the four biomarkers investigated in this study
are adhesion molecules (P-selectin and von Willebrand
factor), while the others (t-PA and PAI-1) are a serine-
protease and its inhibitor primarily involved in the fibrino-
lytic process. Although plasma levels of all four markers
were elevated at baseline, only P-selectin was significantly
reduced by rosuvastatin treatment compared with pla-
cebo. The graphs shown in Figure 1 demonstrate differ-
ences in the distributions of the plasma markers, with a
great variability of PAI-1 values, followed by vWF:Ag, and
less variable values of P-selectin and t-PA.
P-selectin and von Willebrand factor originate from
both platelets and endothelial cells. Endothelial P-selectin
and von Willebrand factor are stored within the Weibel-
Palade bodies and released by a number of stimuli includ-
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